First-in-human randomized placebo-controlled SAD, MAD, and food-effect study of FM101 in healthy volunteers

Phase 1, randomised, double-blind trial of FM101 in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Future Medicine. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory values and 5 more. Started Jan 2019; status: active, not recruiting.